Question · Q2 2026
Ryan Meyers from Lake Street Capital Markets questioned LifeVantage's confidence in returning to growth and winning in the competitive MindBody GLP-1 market, sought clarification on the decision and background for the inventory charge, and asked for insights into the expected revenue split and potential rebound for the third and fourth quarters of fiscal 2026.
Answer
Steve Fife, President and CEO, expressed confidence in the MindBody GLP-1 System due to its natural solution, scientific validation, and appeal to consumers seeking prevention over synthetic drugs. Carl Aure, CFO, explained the inventory charge resulted from initially over-ramping supply due to explosive launch demand, now taking a conservative reserve as demand has normalized. Mr. Aure also projected that MindBody trends have stabilized, and revenue is expected to build from Q3 into Q4, with Q4 likely having a higher proportion due to LoveBiome integration and product rollouts.
Ask follow-up questions
Fintool can predict
LFVN's earnings beat/miss a week before the call

